Follow-The-Filings

Security · featured owners

ARQT Arcutis Biotherapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.1%
  • $33M
  • 1 add 1 exit

ARQT (Arcutis Biotherapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Ron Baron - Bamco Inc. (Baron Capital) is the largest tracked holder by portfolio weight (0.05%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.1% (Ron Baron - Bamco Inc. (Baron Capital)) · not free-float ownership

  1. Ron Baron add 0.05%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 0.05% Add +16.9% 1,253,120 $33M history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 <0.01% Exit 0.00% 26,000 $613K history

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 7 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.07,8.01,9.01 Filing Doc
8-K 9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 13 rows shown

Filed Form Detail Links
4 Period Sep 8, 2026 Filing Doc
4 Period Aug 27, 2026 Filing Doc
4 Period Aug 20, 2026 Filing Doc
4 Period Aug 19, 2026 Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Aug 3, 2026 · 3 forms Filing Doc
4 Period Jul 15, 2026 · 2 forms Filing Doc
4 Period Jun 15, 2026 · 2 forms Filing Doc
4/A Period Jun 5, 2026 Filing Doc
4 Period Jun 5, 2026 · 8 forms Filing Doc
4 Period May 11, 2026 · 2 forms Filing Doc
4 Period May 4, 2026 Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $59.61M $166.54M $372.07M
Gross profit * $54.62M $147.41M $335.38M
Gross margin * 91.6% 88.5% 90.1%
Net income -$262.14M -$140.04M -$16.14M
Net margin * -439.8% -84.1% -4.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $330.43M $335.82M $411.23M
Total non-current assets * $10.93M $13.07M $21.74M
Total assets $341.36M $348.89M $432.97M
Total current liabilities $46.67M $81.01M $129.84M
Total non-current liabilities * $206.03M $110.34M $113.66M
Total equity $88.67M $157.54M $189.48M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$247.06M -$112.16M -$5.62M
Cash from investing $180.23M $28.82M -$30.25M
Cash from financing $101.32M $66.2M $6.97M
Net change in cash $34.45M -$17.37M -$28.74M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders